Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Breakthroughs in therapies for NASH and remaining challenges
Vlad Ratziu, Sven Francque, Arun J. Sanyal
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1263-1278
Open Access | Times Cited: 105

Showing 1-25 of 105 citing articles:

Hepatic inflammatory responses in liver fibrosis
Linda Hammerich, Frank Tacke
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 10, pp. 633-646
Closed Access | Times Cited: 311
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Frank Tacke, Tobias Puengel, Rohit Loomba, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 552-566
Closed Access | Times Cited: 158
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Hao Chen, Huabing Tan, Juan Wan, et al.
Pharmacology & Therapeutics (2023) Vol. 245, pp. 108391-108391
Closed Access | Times Cited: 113
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Maurizio Parola, Massimo Pinzani
Molecular Aspects of Medicine (2023) Vol. 95, pp. 101231-101231
Open Access | Times Cited: 66
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis
Arun J. Sanyal, Vlad Ratziu, Rohit Loomba, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1110-1120
Open Access | Times Cited: 62
FXR agonists in NASH treatment
Luciano Adorini, Michael Trauner
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1317-1331
Open Access | Times Cited: 54
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Paul Brennan, Ahmed M. Elsharkawy, Timothy J. Kendall, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 10, pp. 679-688
Open Access | Times Cited: 50
Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)
Stephen A. Harrison, Carole Thang, Sébastien Bolze, et al.
Journal of Hepatology (2023) Vol. 78, Iss. 5, pp. 914-925
Closed Access | Times Cited: 49
Treating NASH by targeting peroxisome proliferator-activated receptors
Bart Staels, Laura Butruille, Sven Francque
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1302-1316
Open Access | Times Cited: 44
A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1
Suchira Gallage, Adnan Ali, Jose Efren Barragan Avila, et al.
Cell Metabolism (2024) Vol. 36, Iss. 6, pp. 1371-1393.e7
Open Access | Times Cited: 30
Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial
Philip N. Newsome, Arun J. Sanyal, Kristiane Aasen Engebretsen, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 11-12, pp. 1525-1533
Open Access | Times Cited: 26
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
Norbert Stefan, Hannele Yki‐Järvinen, Brent A. Neuschwander‐Tetri
The Lancet Diabetes & Endocrinology (2024)
Open Access | Times Cited: 19
Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation
Cédric Peleman, Sven Francque, Tom Vanden Berghe
EBioMedicine (2024) Vol. 102, pp. 105088-105088
Open Access | Times Cited: 18
Hexokinase 2-mediated metabolic stress and inflammation burden of liver macrophages via histone lactylation in MASLD
Jinyang Li, Xiancheng Chen, Shiyu Song, et al.
Cell Reports (2025) Vol. 44, Iss. 3, pp. 115350-115350
Open Access | Times Cited: 2
Metabolic dysfunction-associated steatotic liver disease in adults
Daniel Q. Huang, Vincent Wai‐Sun Wong, Mary E. Rinella, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access | Times Cited: 2
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
Vlad Ratziu, Stephen A. Harrison, V. Loustaud‐Ratti, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 3, pp. 479-492
Open Access | Times Cited: 58
Treating inflammation to combat non-alcoholic fatty liver disease
Leke Wiering, Frank Tacke
Journal of Endocrinology (2022) Vol. 256, Iss. 1
Open Access | Times Cited: 44
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
Quentin M. Anstee, Kathryn Jean Lucas, Sven Francque, et al.
Hepatology (2023) Vol. 78, Iss. 4, pp. 1223-1239
Open Access | Times Cited: 37
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions
Vlad Ratziu, Marcus Hompesch, Mathieu Petitjean, et al.
Journal of Hepatology (2023) Vol. 80, Iss. 2, pp. 335-351
Open Access | Times Cited: 34
Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies
M.J.M. de Koning, Hilde Herrema, Max Nieuwdorp, et al.
Gut Microbes (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 31
Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease
Florian Plaza Oñate, Célia Chamignon, Sebastian D. Burz, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12232-12232
Open Access | Times Cited: 29
Remnant cholesterol has a non-linear association with non-alcoholic fatty liver disease
Jingfei Chen, Yingjie Su, Xin Su, et al.
Diabetes Research and Clinical Practice (2023) Vol. 201, pp. 110733-110733
Closed Access | Times Cited: 23
Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD
Samer Gawrieh, Eduardo Vilar‐Gómez, Laura Wilson, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 4, pp. 600-608
Closed Access | Times Cited: 14
MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists
Michael Cooreman, Luisa Vonghia, Sven Francque
Diabetes Research and Clinical Practice (2024) Vol. 212, pp. 111688-111688
Closed Access | Times Cited: 10
Hepatic Zbtb18 (Zinc Finger and BTB Domain Containing 18) alleviates hepatic steatohepatitis via FXR (Farnesoid X Receptor)
Lei Zhang, Jiabing Chen, Xiaoying Yang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top